Aim: Cardiospermum halicacabum L. is a climbing plant under Sapindaceae family. The plant leaf is used by traditional healers for treatment of various illnesses. Considering the ethno-medicinal value of C. halicacabum, the present study was taken up to evaluate single-dose acute toxicity study and repeated dose 28-day oral toxicity study (subacute) in Wistar albino rats.

Materials and methods: The hydroalcoholic extract of C. halicacabum leaf was administered orally to Wistar rats as single dose (2000 mg/kg bwt) in acute toxicity study and for continuous 28 days in repeated dose subacute toxicity study at three dose levels (250, 500, and 1000 mg/kg bwt). The study was carried out as per Organisation for Economic Cooperation and Development (OECD) guidelines 423 and 407. Animal mortality and general behavior were observed during the study period.

Results: The study showed that there were no mortality and morbidity in the test groups. The detailed biochemical and hematological investigations evaluated in control and test groups evidenced the safety of the extract as there were no significant differences among control and test groups. Histopathology study in vital organs of test groups showed no significant abnormalities.

Conclusion: The study concluded that the hydroalcoholic extract of C. halicacabum was safe at the prescribed dosages in Wistar albino rats.

Clinical significance: As the safety dosage of the hydroalcoholic extract of C. halicacabum has been proved in Wistar rats, further studies on biological efficacy or biopotency studies can be taken up using these details.

Keywords: Acute and repeated dose 28-day oral toxicity study, Balloon vine, Cardiospermum halicacabum.

How to cite this article: Thamizhselvam N, Surabhi KR, Sanjayakumar YR, Vasanthakumar KG, Gaidhani SN, Radhakrishnan P. Evaluation of Safety of Karnasphota (Cardiospermum halicacabum L.) Leaf through Acute Oral Toxicity Study and Repeated Dose: 28-day Oral Toxicity Study in Wistar Albino Rats. J Drug Res Ayurvedic Sci 2018;3(1):15-22.

Source of support: Nil

Conflict of interest: None